Literature DB >> 17460232

Cardiovascular risks of antiretroviral therapy.

James H Stein.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17460232     DOI： 10.1056/NEJMe078037

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

1.  Development of appropriate coronary heart disease risk prediction models in HIV-infected patients.

Authors:  Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; W Todd Cade; Victor G Dávila-Román; Ralph B D'Agostino; Tarek A Helmy; Matthew Law; Kristin E Mondy; Sharon Nachman; Linda R Peterson; Signe W Worm
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

2.  Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men.

Authors:  Janet Lo; Suhny Abbara; Leon Shturman; Anand Soni; Jeffrey Wei; Jose A Rocha-Filho; Khurram Nasir; Steven K Grinspoon
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

3.  Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.

Authors:  Tricia H Burdo; Janet Lo; Suhny Abbara; Jeffrey Wei; Michelle E DeLelys; Fred Preffer; Eric S Rosenberg; Kenneth C Williams; Steven Grinspoon
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

Review 4.  The spectrum of atherosclerotic coronary artery disease in HIV patients.

Authors:  Abdul Hakeem; Sabha Bhatti; Mehmet Cilingiroglu
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

5.  Impaired diastolic function in naïve untreated human immunodeficiency virus infected patients.

Authors:  Ugo Oliviero; Giovanni Bonadies; Giorgio Bosso; Maria Foggia; Valentina Apuzzi; Mariarosaria Cotugno; Antonio Valvano; Enrico Leonardi; Guglielmo Borgia; Giuseppe Castello; Raffaele Napoli; Luigi Saccà
Journal:  World J Cardiol       Date:  2010-04-26

Review 6.  Cardiovascular complications in HIV management: past, present, and future.

Authors:  Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

7.  The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice.

Authors:  Andrea Mencarelli; Sabrina Cipriani; Barbara Renga; Daniela Francisci; Giuseppe Palladino; Eleonora Distrutti; Franco Baldelli; Stefano Fiorucci
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

8.  Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.

Authors:  Wen Guo; Siu Wong; Jeffrey Pudney; Ravi Jasuja; Ning Hua; Lan Jiang; Andrew Miller; Paul W Hruz; James A Hamilton; Shalender Bhasin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-17       Impact factor: 8.311

9.  Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation.

Authors:  Nicholas T Funderburg; Elizabeth Mayne; Scott F Sieg; Robert Asaad; Wei Jiang; Magdalena Kalinowska; Angel A Luciano; Wendy Stevens; Benigno Rodriguez; Jason M Brenchley; Daniel C Douek; Michael M Lederman
Journal:  Blood       Date:  2009-10-14       Impact factor: 22.113

10.  The Relationship Between HIV Infection and Cardiovascular Disease.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.